Wells Fargo analyst Chris Carey lowered the firm’s price target on Colgate-Palmolive (CL) to $92 from $100 and keeps an Equal Weight rating on the shares. The firm is broadly lowering estimates for the sector ahead of quarterly results. The earnings revisions were anchored by unique, company-specific commodity sheets in all Wells’ models, the firm adds. This makes the margin builds much more specific to the track of this inflationary backdrop, namely into Q4 2026 and 2027, with embedded recovery into 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- Colgate-Palmolive price target lowered to $98 from $100 at UBS
- TD downgrades Colgate-Palmolive on higher oil-based input costs
- Colgate-Palmolive downgraded to Hold from Buy at TD Cowen
- Colgate-Palmolive upgraded to Buy from Hold at Deutsche Bank
- Colgate-Palmolive Announces Global Segment Realignment for 2026
